Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats

Neuroscience

Volumn 213, Issue , 2012, Pages 72-80

  Tizabi, Y ^a   Bhatti, B H ^a   Manaye, K F ^a   Das, J R ^a   Akinfiresoye, L ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Ampa; Ampa receptor; Da; Depression; Fst; Hippocampus; I.p.; Ketamine; Lma; Ne; Nmda; Nmda receptor; Wky; Wky rats

Indexed keywords

AMPA RECEPTOR; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; FORCED SWIMMING TEST; HIPPOCAMPUS; LOCOMOTION; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; RECEPTOR DENSITY; WISTAR KYOTO RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; FEMALE; HIPPOCAMPUS; KETAMINE; RATS; RATS, INBRED WKY; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84861692754     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.03.052     Document Type: Article

References (54)

1. Aan het Rot M., Collins K.A., Murrough J.W., Perez A.M., Reich D.L., Charney D.S., Mathew S.J. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010, 67:139-145.
2. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 15:91-95.
3. 3H]MK-801 binding in rat hippocampal membranes. Neurosci Lett 2000, 296:29-32.
4. Bleakman D., Alt A., Witkin J.M. AMPA receptors in the therapeutic management of depression. CNS Neurol Disord Drug Targets 2007, 2:117-126.
5. Bostwick J.M., Pankratz V.S. Affective disorders and suicide risk: a reexamination. Am J Psychiatry 2000, 157:1925-1932.
6. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 1995, 121:66-72.
7. Du J., Machado-Vieira R., Maeng S., Martinowich K., Manji H., Zarate C. Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. Drug Discov Today Ther Strateg 2006, 4:519-526.
8. Dugovic C., Solberg L.C., Redei E., Van Reeth O., Turek F.W. Sleep in the Wistar-Kyoto rat, a putative genetic animal model for depression. NeuroReport 2000, 11:627-631.
9. Fournier N., Duman R. Role of vascular endothelial growth factor in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression. Behav Brain Res 2011, 1:1-10.
10. Garcia L.S., Comim C.M., Valvassori S.S., Réus G.Z., Andreazza A.C., Stertz L., et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate. Biol Psychiatry 2009, 65:181-184.
11. Getachew B., Hauser S.R., Taylor R.E., Tizabi Y. Effects of desipramine on alcohol-induced anxiety- and depressive-like behaviors in two rat strains. Pharm Biochem Behav 2008, 91:97-103.
12. Ghasemi M., Montaser-Kouhsari L., Shafaroodi H., Ghazi Nezami B., Ebrahimi F., Dehpour A.R. NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test. Psychopharmacology 2009, 206:325-333.
13. Griebel G., Moreau J.L., Jenck F., Misslin R., Martin J.R. Acute and chronic treatment with 5-HT uptake inhibitors differentially modulates emotional responses in anxiety models in rodents. Psychopharmacology 1994, 113:463-470.
14. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009, 61:105-123.
15. Hauser S.R., Getachew B., Taylor R.E., Tizabi Y. Alcohol induced depressive-like behavior is associated with a reduction in central BDNF. Pharmacol Biochem Behav 2011, 100:253-258.
16. Herzog C.J., Corbach B.C.S., Wuttke W., Schulte-Herbrüggen O., Hellweg R., Flügge G., et al. Chronic social instability stress in female rats: a potential animal model for female depression. Neuroscience 2009, 159:982-992.
17. Hevers W., Hadley S.H., Lüddens H., Amin J. Ketamine, but not phencyclidine, selectively modulates cerebellar GABA(A) receptors containing alpha6 and delta subunits. J Neurosci 2008, 28:5383-5393.
18. Hirota K., Sikand K.S., Lambert D.G. Interaction of ketamine with mu2 opioid receptors in SH-SY5Y human neuroblastoma cells. J Anesth 1999, 13:107-109.
19. Holtman J.R., Jing X., Wala E.P. Sex-related differences in the enhancement of morphine antinociception by NMDA receptor antagonists in rats. Pharmacol Biochem Behav 2003, 76:285-293.
20. Kessler R.C., McGonagle K.A., Swartz M., Blazer D.G., Nelson C.B. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord 1993, 29:85-96.
21. Kohli M.A., Lucae S., Saemann P.G., Schmidt M.V., Demirkan A., Hek K., et al. The neuronal transporter gene SLC6A15 confers risk to major depression. Neurons 2011, 70:252-265.
22. Koike H., Iijima M., Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 2011, 224:107-111.
23. Krystal J.H. Ketamine and the potential role for rapid acting antidepressant medications. Swiss Med Wkly 2007, 137:215-216.
24. Lahmame A., del Arco C., Pazos A., Yritia M., Amario A. Are Wistar-Kyoto rats a genetic model of depression resistant to antidepressants?. Eur J Pharmacol 1997, 337:115-123.
25. Lei Y., Yaroslavsky I., Tejani-Butt S.M. Strain differences in the distribution of N-methyl-d-aspartate and gamma (gamma)-aminobutyric acid-A receptors in rat brain. Life Sci 2009, 85:794-799.
26. Li N., Liu R.J., Dwyer J.M., Banasr M., Lee B., Son H., et al. Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011, 69:754-761.
27. Liebrenz M., Borgeat A., Leisinger R., Stohler R. Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Medical Weekly 2007, 137:234-236.
28. Lopez-Rubalcaava C., Lucki I. Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test. Neuropsychopharmacology 2000, 22:191-199.
29. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997, 8:523-532.
30. Machado-Vieira R., Salvadore G., Diazgranados N., Zarate C.A. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 2009, 123:143-150.
31. Machado-Vieira R., Yuan P., Brutsche N., DiazGranados N., Luckenbaugh D., Manji H.K., et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-d-aspartate antagonist. J Clin Psychiatry 2009, 70:1662-1666.
32. MacQueen G., Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research. Mol Psychiatry 2011, 16:252-264.
33. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008, 63:349-352.
34. Mathew S.J., Manji H.K., Charney D.S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008, 33:2080-2092.
35. Mathew S.J., Murrough J.W., Aan Het Rot M., Collins K.A., Reich D.L., Charney D.S. Riluzole for relapse prevention following intravenous ketaminein treatment-resistant depression: a pilot randomized, placebo controlled continuation trial. Int J Neuropsychopharmacol 2009, 17:1.
36. Meagher D., Murray D. Depression. Lancet 1997, 349(Suppl. 1):sI17-sI20.
37. Okamoto N., Nakai T., Sakamoto K., Nagafusa Y., Higuchi T., Nishikawa T. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. J ECT 2010, 26:223-227.
38. Paré W.P., Redei E. Sex differences and stress response of WKY rats. Physiol Behav 1993, 54:1179-1185.
39. Pini S., Cassano G.B., Simonini E., Savino M., Russo A., Montgomery S.A. Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression, and dysthymia. J Affect Disord 1997, 42:145-153.
40. Popik P., Kos T., Sowa-Kucma M., Nowak G. Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology 2008, 198:421-430.
41. Porsolt R.D., Le P.M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
42. Price R.B., Knock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009, 66:522-526.
43. 3H] noradrenaline release from SH-SY5Y cells by reducing calcium influx. Biochem Soc Trans 1995, 3:417S.
44. Skolnick P., Popik P., Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009, 30:563-569.
45. Söderpalm B. The SHR exhibits less " anxiety" but increased sensitivity to the anticonflict effect of clonidine compared to normotensive controls. Pharmacol Toxicol 1989, 65:381-386.
46. Tan S., Rudd J.A., Yew D.T. Gene expression changes in GABA(A) receptors and cognition following chronic ketamine administration in mice. PLoS One 2011, 6:e21328.
47. Tejani-Butt S., Kluczynski J., Paré W.P. Strain-dependent modification of behavior following antidepressant treatment. Prog Neuropsychopharm Biol Psychiatry 2003, 27:7-14.
48. Tizabi Y. Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia. Neurotox Res 2007, 12:233-246.
49. Tizabi Y., Hauser S.R., Tyler K.Y., Getachew B., Madani R., Sharma Y., et al. Effects of nicotine on depressive-like behavior and hippocampal volume of female WKY rats. Prog Neuropsychopharm Biol Psychiat 2010, 34:62-69.
50. Tizabi Y., Overstreet D.H., Rezvani A.H., Louis V.A., Clark E., Janowsky D.S., et al. Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology 1999, 142:193-199.
51. Tizabi Y., Russell L.T., Johnson I., Darmani N.A. Nicotine attenuates DOI-induced head twitch response in mice: implications for Tourette syndrome. Neuropsychopharmacology 2001, 25:1445-1457.
52. Wenk G.L., Barnes C.A. Regional changes in the hippocampal density of AMPA and NMDA receptor across the lifespan of the rat. Brain Res 2000, 885:1-5.
53. Witkin J.M., Marek G.J., Johnson B.G., Schoepp D.D. Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol Disord Drug Targets 2007, 26:87-100.
54. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.